Dr. Thomas Schirrmann is CEO of YUMAB and COO of Corat Therapeutics. He is biochemist by training and holds a PhD in immunology. He has more than 20 years expertise in research for immunotherapies and antibody technologies and published 70+ scientific articles. Thomas is co-founder and CEO of YUMAB. In May 2020, he founded Corat Therapeutics to bring a COVID-19 antibody program fast track into the clinics.